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The development and progression of atherosclerosis comprises various processes, 
such as endothelial dysfunction, chronic inflammation, thrombus formation and lipid 
profile modification.  Statins are HMG-CoA reductase inhibitors that have 
pleiotropic effects in addition to cholesterol lowering properties.  However, the 
mechanisms of these effects are not completely understood.  Here, we investigated 
whether atorvastatin affects the levels of malondialdehyde-modified low-density 
lipoprotein (MDA-LDL), an oxidized LDL, the proinflammatory cytokine 
interleukin-6 (IL-6), or platelet P-selectin, a marker of platelet activation, relative to 
that of LDL cholesterol (LDL-C).  Forty-eight patients with coronary artery disease 
and hyperlipidemia were separated into 2 groups that were administered with 
(atorvastatin group) or without (control group) atorvastatin.  The baseline 
MDA-LDL level in all participants significantly correlated with LDL-C (r = 0.71, p < 
0.01) and apolipoprotein B levels (r = 0.66, p < 0.01).  Atorvastatin (10 mg/day) 
significantly reduced the LDL-C level within 4 weeks and persisted for a further 8 
weeks of administration.  Atorvastatin also reduced the MDA-LDL level within 4 
weeks and further reduced it over the next 8 weeks.  Platelet P-selectin expression 
did not change until 4 weeks of administration and then significantly decreased at 12 
weeks, whereas the IL-6 level was gradually, but not significantly, reduced at 12 
weeks.  In contrast, none of these parameters significantly changed in the control 
group within these time frames.  The reduction (%) in IL-6 between 4 and 12 weeks 
after atorvastatin administration significantly correlated with that of MDA-LDL and 
of platelet P-selectin (r = 0.65, p < 0.05 and r = 0.70, p < 0.05, respectively). 
These results suggested that the positive effects of atorvastatin on the LDL-C 
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oxidation, platelet activation and inflammation that are involved in atherosclerotic 
processes are exerted in concert after lowering LDL-C. 





Oxidized low-density lipoprotein (LDL) is believed to play a key role in the 
pathogenesis of coronary atherosclerosis, which is a multifactorial condition that 
includes endothelial dysfunction, chronic inflammatory responses, plaque instability 
and thrombus formation.  The oxidation of LDL alters its native properties and allows 
scavenger receptors to incorporate it into macrophages where it negatively affects 
various functions in the vascular walls, such as the inhibition of endothelial nitric oxide 
(NO) production, endothelial apoptosis and the proliferation of smooth muscle cells1.  
Malondialdehyde-modified LDL (MDA-LDL; an oxidized LDL) has been isolated from 
the sera of patients with coronary artery diseases (CAD)2 and levels are elevated in 
patients with CAD, diabetes mellitus (DM) and hyperlipidemia3-6.  Furthermore, 
circulating levels of MDA-LDL correlate with the intima-media thickness of carotid 
arteries7.  These suggest that MDA-LDL could be a good indicator of atherosclerosis. 
Platelets are prominent components of thrombi and their activation is a key step in 
the progression of atherosclerosis.  Indeed, atherectomy in patients with myocardial 
infarction has revealed that activated platelets are located close to atherosclerotic 
plaque8.  P-selectin, a marker of platelet activation, is related to the magnitude of the 
distribution of atherosclerosis in patients with coronary artery disease and/or peripheral 
arterial disease9.  Furthermore, P-selectin expression on platelets is elevated in patients 
with atherosclerotic ischemic stroke10 or hypercholesterolemia11.  Johnson et al.12 also 
demonstrated that fatty streaks were smaller in the aortae of mice that were 
P-selectin-deficient than in those that were P-selectin-positive.  Thus, platelet 
P-selectin expression might be an important factor in the atherothrombotic process13. 
The proinflammatory cytokine, interleukin-6 (IL-6), is a powerful inducer of 
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C-reactive protein (CRP)14, which is a useful predictor of coronary artery events15-17.  
Reports indicate that increased levels of circulating IL-6 are also related to a high risk of 
mortality due to myocardial infarction and coronary heart disease18,19.  Interleukin-6 
can interfere with lipid metabolism by down-regulating lipoprotein lipase and 
modulating the immune response of vascular cells20-22. 
Although oxidized-LDL, platelet P-selectin and IL-6 contribute to the development 
and progression of atherosclerosis as noted above, associations among these factors 
remain obscure. 
Statins are HMG-CoA reductase inhibitors that can reduce the likelihood of 
cardiovascular events independently of their ability to lower cholesterol; that is, statins 
are pleiotropic23-26.  The molecular mechanisms of pleiotropic effects involve 
increased endothelial NOS expression through inhibiting geranylgeranylation of the 
small GTP-binding protein, Rho27, a post-translational activator of the 
phosphatidylinositol 3-kinase/Akt pathway28, and interaction with heat shock protein 
9029.  Such modulation of the intracellular signaling pathway leads to improved 
endothelial and platelet function and suppresses vascular inflammation30-32.  However, 
whether or not these beneficial properties of statins are interrelated remains unknown, 
particularly in the clinical setting. 
The present study found that atorvastatin reduced the levels of MDA-LDL and 
P-selectin on the surface of platelets and of IL-6 in patients with CAD and 
hyperlipidemia.  These changes were inter-related at 4 and 12 weeks of atorvastatin 
administration, and subsequently associated with decreased cholesterol values. 
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Materials and methods 
We enrolled 48 consecutive patients with hypercholesterolemia and CAD 
confirmed by coronary angiography between August, 2000 and August, 2001.  The 
patients were evaluated according to the Japanese Atherosclerosis Society 
guidelines for the diagnosis and treatment of atherosclerotic cardiovascular diseases, 
and then randomly separated into one group that received 10 mg of oral atorvastatin 
daily for 12 weeks with diet therapy and another (control) that received only diet 
therapy for 12 weeks.  Table 1 shows the characteristics of the patient groups.  
All were stabilized at the start of this study, had been administered with aspirin as 
an antiplatelet agent and had not changed other prescribed medications such as 
ACE inhibitors, -blockers, Ca-channel antagonists or diuretics.  Four patients 
were excluded from the atorvastatin group because of side effects, liver dysfunction 
and elevated creatinine kinase.  All patients provided written, informed consent 
and all procedures followed institutional guidelines. Appropriate treatment was 
applied, including the administration of statins to the control group after completion 
of this study. 
Blood samples were collected from both groups immediately before, and at 4 
and 12 weeks after the start of the study. 
The level of P-selectin on platelet membranes was analyzed by whole-blood 
flow cytometry essentially as described33.  In brief, peripheral blood samples were 
collected using a tourniquet from resting patients without venous return occlusion, 
into K3 EDTA Vacutainers.  Thereafter, they were fixed in 1.0% 
formaldehyde/PBS for at least 2 hours at 4°C, washed twice with 0.1% sodium 
azide/PBS and incubated with monoclonal fluorescein isothiocyanate 
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(FITC)-conjugated anti-CD62P and phycoerythrin (PE)-conjugated anti-CD41 for 
15 min at room temperature in the dark.  The surface expression of CD62P 
(P-selectin) and CD41 (GP IIb/IIIa), a specific platelet antigen was determined by 
flow cytometry using a FACSCAN (BECTON Inc., USA).  The platelets were 
gated by CD41 staining and transferred to FL 1 (CD62P-FITC) on the x axis and 
FL 2 (CD41-PE) on the y axis in the histogram shown in Fig. 1.  Platelet 
P-selectin levels are expressed as %CD62P positive cells among 50,000 platelets 
(CD41 positive cells).  Non-specific immunostaining for CD62P or CD41 was 
determined using an irrelevant isotype IgG-FITC or -PE conjugated as a negative 
control.  Fasting venous blood samples were collected between 6:00 and 8:00 a.m. 
to measure other parameters. Sera were analyzed for total cholesterol, LDL 
cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triglycerides 
(TG), apolipoprotein B (apo-B), apolipoprotein AI (apo-AI) and creatinine kinase 
(CK) levels, whereas renal profiles, liver function and prothrombin time (PT) were 
determined using routine laboratory techniques at our hospital.  Levels of 
MDA-LDL were measured using a sandwich enzyme-linked immunosorbent assay 
(ELISA) (SRL Inc., Tokyo).  Levels of serum IL-6 were measured using a 
sandwich ELISA (Fujirebio Inc., Tokyo). 
The % change in levels of parameters was calculated by subtracting the value 
obtained before, from that obtained after 2 examinations and dividing the result by 
the levels obtained before. 
Statistical analysis:  All results are expressed as means ± SD.  Differences 
between 2 groups were analyzed using Student’s t-test or the Mann-Whitney test.  
Changes in levels of parameters before, and at 4 and 12 weeks after treatment were 
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compared using repeated measures ANOVA, followed by the Bonferroni post hoc 
test.  Correlations between 2 variables are described using Pearson’s or 
Spearman’s rank correlation.  All data were statistically analyzed using SPSS II 





Relationships among baseline MDA-LDL, platelet p-selectin, IL-6 and lipid 
profiles. 
The baseline lipid profile of the patients was as follows (mg/dl): 213.5 ± 17.9 total 
cholesterol, 135.1 ± 16.8 LDL-C, 150.4 ± 56.4 TG and 49.2 ± 16.4 HDL-C (means ± 
SD), indicating hyper-LDL-cholesterolemia.  The levels of MDA-LDL, P-selectin and 
IL-6 were not as elevated as those in previous reports3,34-36, suggesting that CAD was 
stable in our patients.  In this setting, MDA-LDL significantly correlated with LDL-C 
(r = 0.71, p < 0.01) and apo-B (r = 0.66, p < 0.01), but not with TG and HDL-C (Fig. 2).  
No relationships among baseline P-selectin, MDA-LDL and IL-6 were identified (Fig. 
3). 
Effects of atorvastatin on MDA-LDL, P-selectin, IL-6 and lipid profiles at 4 and 12 
weeks after administration. 
Table 1 shows that age, gender, BMI, lipid profiles and complications of 
hypertension and diabetes mellitus did not significantly differ between the 2 groups of 
patients. 
Atorvastatin (10 mg/day) significantly reduced LDL-C levels after 4 and 12 weeks 
of administration (28.2% and 26.7% reduction, respectively).  In contrast, the level did 
not change in the control group after dietary therapy over the same period (Fig. 4).  
Furthermore, levels of HDL-C and TG also significantly differed at 4 and 12 weeks of 
administration compared with the control group (Fig. 4).  The MDA-LDL 
concentration decreased after 4 and 12 weeks of atorvastatin administration compared 
with that before treatment, but did not significantly differ from that of the control group 
(p = 0.08 and p = 0.05 at 4 and 12 weeks, respectively) (Fig. 5).  The platelet P-selectin 
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level was not obviously changed after 4 weeks of atorvastatin administration, but 
significantly decreased after 12 weeks (Fig. 5).  The levels of P-selectin in the control 
group before and at 4 weeks after administration were lower than that of the atorvastatin 
group, and dietary therapy did not significantly affect the levels until 12 weeks.  In 
contrast, PT, an indicator of the extrinsic coagulation pathway, did not significantly 
change in either group (Fig. 5).  Atorvastatin tended to gradually reduce the IL-6 
concentration over 12 weeks, but the difference was not significant, which might be due 
to high variance (Fig. 5). 
To investigate whether the changes induced by atorvastatin are interrelated, or are 
related to its LDL-lowering effect, we analyzed correlations as %change among 
MDA-LDL, P-selectin, IL-6 and LDL-C.  Table 2 shows that the %change of 
MDA-LDL tended to positively correlate with that of LDL-C (r = 0.48, p = 0.09) 
between before and at 4 weeks after atorvastatin therapy.  At between 4 and 12 weeks 
after treatment, correlations between MDA-LDL and IL-6 and between P-selectin and 
IL-6 were significant, but none of them correlated with LDL-C. 
No serious CAD complications such as acute coronary syndrome, heart failure, 




The present study shows that MDA-LDL correlated with LDL-C at baseline.  We 
also showed that atorvastatin induced a change in the level of MDA-LDL at between 4 
and 12 weeks after administration that was associated with changes in IL-6, but not in 
LDL-C levels.  Moreover, the change in platelet activation detected by P-selectin 
expression on the surface was related to that of IL-6. 
The oxidative modification of LDL-C is believed to play an important role in the 
progression of atherosclerosis37.  Tanaga et al.6 demonstrated that the level of 
MDA-LDL is higher in patients with, than without CAD, and correlated with LDL-C, 
TG, HDL-C as well as with LDL particle size.  The correlation of LDL with 
MDA-LDL in the present study was consistent with their findings.  However, we could 
not find any correlation between TG and HDL.  The lipid profiles including LDL-C, 
TG and HDL in our patients were slightly worse than theirs.  Differences in patient 
characteristics and numbers might have contributed to the discrepancy.  After 
atorvastatin administration, MDA-LDL tended to fall for 12 weeks, and the %change 
tended to correlate with that of LDL between before and at 4 weeks and significantly 
correlated with changes of IL-6 between 4 and 12 weeks.  These results suggested that 
atorvastatin regulates oxidization partially through lowering LDL, and then by affecting 
inflammatory reactions in damaged vessels independently of this property.  Tamura et 
al.3 described that the removal of substantial amounts of ‘aged’ LDL, which is prone to 
oxidation in the circulation, through LDL receptor activity up-regulated by statins could 
contribute to reducing the susceptibility of ‘new’ LDL in the circulation to oxidation, 
resulting in a reduced level of circulating MDA-LDL.  Statins and/or their metabolites 
have antioxidant effects that are markers of both a reduction in generalized oxidative 
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stress and of LDL susceptibility to oxidation 38.  Massy et al.39 demonstrated that 
oxidized as well as native LDL stimulates IL-6 mRNA expression and secretion in 
human mesangial cells, a process that lovastatin (5 M) can suppress within 16 h.  The 
acute phase inflammatory protein, CRP, which is produced by IL-6 stimulation in 
hepatocytes, also positively correlates with oxidized LDL, and both CRP and IL-6 are 
indicators of event-free survival in patients with unstable angina35.  Moreover, 
Sugiyama et al.40 demonstrated that 4 weeks of treatment with 10 mg/day of atorvastatin 
significantly decreased CRP levels in hyperlipidemic patients.  We did not find here 
that 10 mg/day of atorvastatin significantly reduced IL-6.  The MIRACL study found 
that atorvastatin at 80 mg/day for 16 weeks reduces CRP but does not significantly 
reduce IL-6.  This might be due to the greater diurnal variability and shorter half-life of 
IL-6 compared with CRP34.  Marz et al.41 also found that statins significantly lower 
CRP but not IL-6 and inferred that statins lower CRP by interfering with the regulation 
of hepatic CRP production by IL-6 rather than by directly modulating inflammatory 
processes in vessel walls.  Therefore, changes should be more obvious if CRP is 
measured as a marker of inflammation. 
Atorvastatin in our patients did not obviously alter the level of P-selectin on the 
platelet surface until 4 weeks of administration, and then significantly reduced the 
amount thereafter up to 12 weeks of administration, which was associated with a 
reduction in IL-6.  Several reports have shown that statins reduce the expression of 
P-selectin in patients with hypercholesterolemia and/or atherothrombosis11,13,36,42-44.  
Significant effects start to appear from within 9 days to 6 months, which might be due 
to different study protocols, different types of statins and the patient population.  
Others have examined soluble P-selectin as a marker of platelet activation.  Here, we 
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examined P-selectin expression on the surface of platelets by flow cytometry, because 
soluble P-selectin in plasma samples originates not only from platelets but also 
endothelium.  Gurbel et al.45 found that soluble and platelet P-selectin did not correlate 
in 300 patients with chest pain.  Therefore, flow cytometry is a reliable and sensitive 
method of detecting platelet activation46.  The changes in platelet P-selectin and IL-6 
between 4 and 12 weeks after atorvastatin administration were significantly associated.  
Interleukin-6 is thought to be not only proinflammatory but also procoagulant, 
stimulating the synthesis of fibrinogen, plasminogen-activator inhibitor type I and tissue 
factor47.  Platelet activation determined as platelet P-selectin in response to thrombin 
and platelet activating factor (PAF) is enhanced in dogs treated with IL-648.  Another 
proinflammatory cytokine, TNF-, also promotes a procoagulant state by inhibiting the 
synthesis of anticoagulant protein C 49 and by eliciting tissue factor production on the 
endothelium and monocytes, thereby stimulating thrombin and fibrin formation50.  
Furthermore, fluvastatin (80 mg/day for 12 weeks) decreased the level of IL-6 and 
TNF- in patients with chronic heart failure51.  Thus, atorvastatin can modulate the 
expression of IL-6, which might have interacted with platelet activation after reducing 
LDL-C in the present study.  
The significant correlation between MDA-LDL with IL-6 and the tendency towards 
a positive correlation between MDA-LDL and P-selectin induced by atorvastatin 
indicate that LDL-C oxidation, inflammation and platelet activation interact and that 
atorvastatin improves these factors in a delayed manner associated with its cholesterol 
lowering effects.  Indeed, oxidized LDL induces P-selectin expression in human 
endothelial cells that are involved in mediating monocyte adhesion52.  This mechanism 
is involved in the down-regulation of NO synthesis53, the inhibition of platelet plasma 
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membrane Ca2+-ATPase54 and the modulation of intracellular signaling via 
Rho-kinase55 and phospholipase A256 in platelets.  Atorvastatin reduces the expression 
of platelet CD36 and LOX-1, which are oxidized LDL receptors, in association with 
decreased platelet-associated oxidized LDL, resulting in platelet deactivation11.  
Schafer et al.57 also demonstrated that rosuvastatin reduces platelet activation by 
enhancing endovascular NO bioavailability in rats with chronic heart failure. 
Although the precise relationships among oxidized-LDL, platelet P-selectin and 
IL-6 remain unknown, some investigators have shown that they are involved in the 
pleiotropic effects of statins. 
All patients in the present study with CAD were administered with aspirin, which is 
a potent anti-platelet agent that might have affected the platelet surface expression of 
P-selectin.  Moreover, the levels of P-selectin at baseline and at 4 weeks in the control 
group were lower than those in the atorvastatin group, although the features of the 
participants including age, gender, lipid profile and nature of disease did not 
significantly differ between the groups for reasons that remain unclear. Further studies 
of large populations including normal controls are required.  We also did not 
investigate the short or long term effects of various doses or types of statins, including 
the incidence of CAD. 
In conclusion, we demonstrated that atorvastatin lowers LDL-C and subsequently 
reduces MDA-LDL and platelet P-selectin that are associated with the reduction of IL-6 
in patients with CAD and high levels of LDL-C.  Atorvastatin might ameliorate the 
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Fig. 1. Representative flow cytometry histograms and dot plots.   
Upper, negative control (IgG); lower, patient’s blood sample. Expression of platelet 
P-selectin was determined as CD62P positive cells gated by CD41 positive staining.  
All data are results of 50,000 total events. 
 
Fig. 2. Relationship between MDA-LDL and lipid profile at baseline. 
Relationships between MDA-LDL and LDL-C (left upper), apo B (right upper), TG 
(lower left) and HDL-C (lower right). 
 
Fig. 3. Relationships between platelet P-selectin and MDA-LDL and IL-6. 
Left, correlation between P-selectin and MDA-LDL; right, correlation between 
P-selectin and IL-6. 
 
Fig. 4. Changes in lipid profile before, and after atorvastatin for 4 and 12 weeks.  
Closed circles and squares, atorvastatin and control groups, respectively.  Changes 
in MDA-LDL (upper left), apo B (upper right), TG (lower left) and HDL-C (lower 
right).  * P < 0.05, ** P < 0.01. 
 
Fig. 5. Changes in MDA-LDL, IL-6, P-selectin and PT before, and after 
atorvastatin for 4 and 12 weeks. 
Closed circles and squares indicate atorvastatin and control groups, respectively.  
Upper left, MDA-LDL; upper right, IL-6; lower left, P-selectin; lower right, PT. *, 
P < 0.05; **, P < 0.01. 
Table 1.  Characteristics of patients at baseline. 
 
 Atorvastatin Control P value
Number 25 23  
Gender (male/female) 14/11 13/10 NS 
Age (y) 68.9±8.2 66.2±6.8 NS 
BMI (kg/m2) 25.8±3.1 23.9±5.6 NS 
Total cholesterol (mg/dl) 215.2±22.6 211.7±10.8 NS 
HDL-C (mg/dl) 51.9±21.5 46.2±7.4 NS 
LDL-C (mg/dl) 135.8±19.4 132.2±13.7 NS 
TG (mg/dl) 137.0±62.4 165.1±45.8 NS 
Hypertension (%) 53 43.5 NS 
Diabetes mellitus (%) 20 26 NS 
Smoking (%) 36 21.7 NS 
Underlying diseases AP/MI 12/13 15/8 NS 
HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein 
cholesterol; TG, triglycerides; AP, angina pectoris; MI, myocardial infarction; NS, not 
significant.   
Table 2.  Correlations among % changes in MDA-LDL, P-selectin, IL-6 and LDL-C 
 
 Correlation coefficient P value 
% Change between before and 4 weeks later   
LDL-C vs. MDA-LDL 0.48 0.09 
LDL-C vs. P-selectin 0.42 0.13 
LDL-C vs. IL-6 0.05 0.45 
MDA-LDL vs. P-selectin -0.17 0.33 
MDA-LDL vs. IL-6 -0.28 0.24 
P-selectin vs. IL-6 0.18 0.32 
% change between 4 and 12 weeks later   
LDL-C vs. MDA-LDL 0.20 0.31 
LDL-C vs. P-selectin -0.05 0.42 
LDL-C vs. IL-6 0.40 0.16 
MDA-LDL vs. P-selectin 0.47 0.11 
MDA-LDL vs. IL-6 0.65 0.04 
P-selectin vs. IL-6 0.70 0.03 
% change between before and 12 weeks later   
LDL-C vs. MDA-LDL 0.53 0.06 
LDL-C vs. P-selectin 0.31 0.32 
LDL-C vs. IL-6 0.22 0.48 
MDA-LDL vs. P-selectin 0.41 0.14 
MDA-LDL vs. IL-6 0.27 0.37 
P-selectin vs. IL-6 0.29 0.35 
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